Advertisement

Topics

Foamix Ltd Company Profile

21:26 EDT 25th September 2018 | BioPortfolio

Foamix Ltd. is a leading developer of topical and mucosal foams for dermatological and gynecological applications. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is currently collaborating with pharmaceutical and cosmetic companies on a range of projects in the development of proprietary dermatological and gynecologic foam products. Additionally, the Company has an in-house pipeline of dermatological and gynecological formulations in foam presentation. Foamix's psoriasis foam product licensed to Dr. Reddy's Laboratories and marketed by Promius Pharma under the trade mark Scytera(TM) was launched in the United States in early 2009.


News Articles [23 Associated News Articles listed on BioPortfolio]

Foamix plans $70m offering after acne trial success

Foamix Pharmaceuticals intends to market its acne treatment by itself.

Foamix completes dosing in FX2016-11 and FX2016-12 studies

Foamix Pharmaceuticals has completed patient enrolment and dosing in the FX2016-11 and FX2016-12 studies designed to treat moderate-to-severe papulopustular rosacea....Read More... The post Foamix com...

Foamix Pharma's acne drug meets main goals in late-stage trial

Foamix Pharmaceuticals Ltd said on Tuesday that its drug treating moderate-to-severe acne met the main goals of its third late-stage study.

Foamix acne drug meets main goals in late-stage trial, shares surge

Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading. ...

Foamix to file acne treatment after successful late-stage trials

Israel's Foamix has said it is planning a US filing of its minocycline-based topical acne treatment after positive late stage trial results. The third phase 3 trial of FMX101, a topical minocycline ...

Foamix Is Headed For Dilution

Foamix raises $70M following Phase III acne readout

Foamix's minocycline foam meets in third Phase III for acne

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Foamix Ltd

Foamix Ltd. is a leading developer of topical and mucosal foams for dermatological and gynecological applications. Foamix's state-of-the-art foams provide controlled delivery of a variety of activ...

More Information about "Foamix Ltd" on BioPortfolio

We have published hundreds of Foamix Ltd news stories on BioPortfolio along with dozens of Foamix Ltd Clinical Trials and PubMed Articles about Foamix Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Foamix Ltd Companies in our database. You can also find out about relevant Foamix Ltd Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Psoriasis
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...


Corporate Database Quicklinks



Searches Linking to this Company Record